Terms ending in 2038
Every in-force patent on Ono Pharmaceutical Co., Ltd.'s record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,836,747 | Ethane-Sulfonate Salt of Quinoline Derivative In force · High confidence | Ono Pharmaceutical Co., Ltd. | In force | High confidence | |
| US 11,851,428 | Activator of Trek (TWIK Related K+ Channels) Channels In force · High confidence | Ono Pharmaceutical Co., Ltd. | In force | High confidence | |
| US 11,479,550 | EP4 Antagonist In force · High confidence | Ono Pharmaceutical Co., Ltd. | In force | High confidence | |
| US 11,826,363 | Therapeutic Agent for Solid Cancers, Which Comprises Axl Inhibitor as Active Ingredient In force · High confidence | Ono Pharmaceutical Co., Ltd. and Kyoto Prefectural Public University Corporation | In force | High confidence | |
| US 10,617,667 | Method for Treating Brain Tumors In force · High confidence | The Regents of the University of California | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Ono Pharmaceutical Co., Ltd..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.